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INTRODUCTION
By 2050, the number of people living with Alzheimer’s 
disease (AD), an age-related neurodegenerative disor-
der, or other dementias in the United States is projected 
to nearly double from 48 million to 88 million 1. There-
fore, considering the public health impact of AD and 
the absence of available disease-modifying therapies 
for AD treatment 2, there is a great need in preventing 
the onset of the disease and slowing AD progression. 
In the last two decades, in addition to cardiovascular 
risk factors, several observational studies suggested a 
wide variety of potentially modifiable risk factors for late-
life cognitive impairment and AD such as psychological 
Given the impact of nutrition on neuroprotection largely investigated in observational studies, in the present 
article, we reviewed evidence from randomized clinical trials (RCTs) published in the last three years (2014-
2016) exploring nutritional intervention efficacy in slowing cognitive impairment progression and achieving 
cognitive-related outcomes in patients aged 60 years and older with mild cognitive impairment (MCI), preclin-
ical Alzheimer’s disease (AD), prodromal AD, AD, unspecified dementia, and vascular dementia using different 
levels of investigation (i.e., medical food/nutraceutical supplementation/multidomain approach and dietary 
food/macro- and micronutrient approaches). From the reviewed RCTs, there was emerging evidence that nutri-
tional intervention through medical food/nutraceutical supplementation (Fortasyn Connect® and another sim-
ilar nutraceutical formulation) and multidomain approach improved magnetic resonance imaging findings and 
other cognitive-related biomarkers, but without clear effect on cognition in mild AD and MCI. Moreover, there 
was some evidence of a positive effect of antioxidant-rich foods (nuts) in improving specific cognitive domains 
and cognitive-related outcomes in MCI and mild-to-moderate dementia, but only in small samples. There was 
also convincing evidence for fatty acid supplementation, mainly n-3 polyunsaturated fatty acids (PUFAs), in 
improving specific cognitive domains and/or cognitive-related biomarkers in MCI and AD. Furthermore, antiox-
idant vitamin and trace element supplementations improved only cognitive-related outcomes and biomarkers, 
without effect on cognitive function in AD and MCI patients. Finally, high-dose B vitamin supplementation in AD 
and MCI patients improved cognitive outcomes but only in the subjects with a high baseline plasma n-3 PUFA, 
while folic acid supplementation had positive impact on specific cognitive domains. 
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conditions, education level, engagement in social and 
mentally stimulating activities, sensory changes, and 
lifestyle including diet, physical activity and voluptuary 
habits 3 4. In particular, several nutritional supplements 
have been studied for their potential role as neuropro-
tective interventions in AD and cognitive disorders in 
older age.5 This protective effect could be mediated by 
several pathobiological pathways involved in AD devel-
opment such as amyloid-β (Aβ) deposition, neurofibril-
lary degeneration, synapse loss, inflammation, oxida-
tive stress, mitochondrial dysfunction, loss of vascular 
integrity, and neuronal injury. In particular, late-life cog-
nitive disorders were associated with synaptic abnor-
malities and dysfunction 6, the last currently considered 
as one of the pathological hallmarks of AD 7. Therefore, 
several observational studies and randomized clinical 
trials (RCTs) have proposed nutritional interventions as 
preventive or therapeutic approaches in order to slow 
the progression of cognitive impairment in older sub-
jects or reducing AD risk and progression. In particular, 
several meta-analyses and systematic/scoping reviews 
investigated the efficacy of different nutritional supple-
mentations in preventing late-life cognitive disorders in 
cognitively healthy older adults with encouraging find-
ings  8-12. Some of these studies found that n-3 poly-
unsaturated fatty acids (PUFAs) were associated with 
improved global cognition and some specific cognitive 
domains, magnetic resonance imaging (MRI) findings, 
and/or cognitive-related biomarkers  9-12. B  vitamins, 
and vitamin  E supplementations did not affect cog-
nition  8 or had limited efficacy  9 11 12, while adherence 
to the Mediterranean diet was significantly associated 
with better cognitive performance and less cognitive 
decline 10 12. Moreover, for patients with mild cognitive 
impairment (MCI), AD, or dementia, there were fewer 
systematic reviews and meta-analyses investigating 
RCTs conducted on nutritional intervention 13-16.
Furthermore, in the last years, according to the Nation-
al Institute on Aging-Alzheimer’s Association (NIA-AA) 
guidelines for AD due to AD pathology 17 and Internation-
al Working Group (IWG)-1 18 and IWG-2 criteria for AD 19, 
it has been suggested a direct impact of nutrition on 
brain structure and activity changes 4. Furthermore, there 
was an increased need to objectively quantify the effects 
of nutrients on cognitive-related outcomes not only in 
terms of cognitive scores o clinical scales, so opening 
the era of brain imaging biomarkers also for nutritional 
epidemiology  20. Finally, the use of objective measures 
of dietary habits, not only using daily semi-quantitative 
food frequency questionnaires, but also biochemical 
markers (e.g., serum concentration or red blood cells 
levels), also emerged to achieve more reliable findings. 
The present study sought to provide a comprehensive 
systematic review of the RCTs published in the past 
three years (2014-2016) about nutritional intervention 
efficacy in slowing cognitive impairment progression and 
achieving cognitive-related outcomes in patients aged 
60  years and older with late-life cognitive disorders, 
i.e., MCI, preclinical AD, prodromal AD, AD, unspecified 
dementia, and vascular dementia (VaD), using different 
levels of investigation (i.e., medical food/nutraceutical 
supplementation/multidomain approach and dietary 
food/macro- and micronutrient approaches). 
NUTRITIONAL INTERVENTION THROUGH 
MEDICAL FOOD/NUTRACEUTICAL 
SUPPLEMENTATION AND MULTIDOMAIN 
APPROACH
Medical foods/nutraceuticals
Table I shows selected RCTs published in the last three 
years that evaluated the efficacy of nutritional inter-
vention through medical foods/nutraceutical supple-
mentation and multidomain approach in the treatment 
of patients with late-life cognitive disorders aged over 
60 years 21-27. Therefore, it is likely that the potency of 
single nutrients may be insufficient to achieve a clinical-
ly relevant benefit  5. Based on the increasing body of 
evidence about the potential beneficial effect of specific 
nutrients properly combined, several RCTs investigat-
ed medical foods and nutraceutical supplementations 
characterized by a specific well studied combination of 
nutrients in different phases of cognitive dysfunction. 
Several medical foods and multinutrient interventions 
have been tested showing promising findings, not only 
in earlier phases of cognitive impairment 5.
Fortasyn Connect®
The medical food Fortasyn Connect® contains a spe-
cific nutrient combination of docosahexaenoic acid 
(DHA) 1200  mg, eicosapentaenoic acid (EPA) 300  mg, 
uridine monophosphate 625  mg, choline 400  mg, folic 
acid 400 mcg, vitamin B6 1   mg, vitamin B12 3 mcg, 
vitamin C 80  mg, vitamin E 40  mg, selenium 60 mcg, 
and phospholipids 106   mg, designed to ameliorate 
synapse loss, synaptic dysfunction, and other patho-
logical pathways affected in AD patients 28. In fact, sev-
eral neuroprotective effects of Fortasyn Connect® have 
been reported in preclinical studies such as increases 
in markers of synaptogenesis 29, neurotransmitter syn-
thesis and release 29, and cerebral blood flow 30, preser-
vation in matter integrity 30, reduction in Aβ production 
and toxicity  31, and restoration of neurogenesis  32. In 
two previous RCTs, Souvenir I 33 and Souvenir II 34, For-
tasyn Connect®  improved memory performance in mild 
AD patients not taking AD medications. In particular, in 
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Souvenir  I, Fortasyn Connect® significantly improved 
delayed verbal recall test of the Wechsler Memory Scale 
revised edition (WMS-r) in mild AD patients [Mini Mental 
State Examination (MMSE) score 20-26] after 12 weeks 
of intervention versus placebo without effects on the 
13-item modified Alzheimer’s Disease Assessment 
Scale cognitive subscale (ADAS-cog) 33. In Souvenir II, 
significant improvements on the memory domain com-
posite z-score based on a Neuropsychological Test Bat-
tery (NTB) during the 24 weeks were observed in mild 
AD patients (MMSE score ≥ 20) 34. In addition, an ex-
ploratory analysis of results from a 24-week open-label 
extension (OLE) of Souvenir II suggested that memory 
function improved throughout 48 weeks in patients with 
mild AD taking Fortasyn Connect® 35. However, a third 
RCT, the S-Connect study, in patients with mild-to-
moderate AD (MMSE score 14-24) receiving AD medi-
cations did not show any Fortasyn Connect® effects on 
cognition 36. In a recent effect size analysis conducted 
on Souvenir I, Souvenir II, S-Connect, and the OLE of 
Souvenir  II, in patients with mild AD, effect sizes were 
0.21 [95% confidence interval (CI): -0.06, 0.49] for the 
primary outcome in Souvenir II (NTB z-score) and 0.20 
(95% CI: 0.10, 0.34) for the co-primary outcome of 
Souvenir I (WMS-r delayed recall). No effect was shown 
on cognition in patients with mild-to-moderate AD (S-
Connect) 37. Recently, a biomarker panel of ten plasma 
lipids, including 8 phosphatidylcholine species, showed 
to predict conversion from cognitive normal aged adults 
to amnestic MCI or AD within 2-3 years with >  90% 
accuracy  38, with the reduced levels of these plasma 
phospholipids reflecting altered phospholipid metabo-
lism in the brain and periphery. Using data from the 
Souvenir  II  34, a 24-week intervention with Fortasyn 
Connect® in 96 drug-naıve patients with very mild to 
mild AD significantly increased 5 of the 7 measured 
biomarker phosphatidylcholine species (Tab. I) 21, sug-
gesting that this nutritional intervention could be useful 
in asymptomatic subjects with a plasma lipid biomarker 
profile prognostic of AD. Considering synaptic loss as 
an early pathological hallmark in AD related to memory 
impairment, macroscopic brain activity modifications 
measured with electro- and magnetoencephalography 
(EEG and MEG) might indicate synaptic changes in AD 
and has been proposed to identify nutritional interven-
tion effects in clinical trials. In an interesting RCT was 
investigated the Fortasyn Connect® effects on synap-
tic integrity and function, assessed by advanced EEG 
analysis, considering brain activity-based networks as 
a derivative of underlying synaptic function (Tab.  I)  22. 
In this RCT, 179 drug-naïve mild AD patients were 
randomised to receive Fortasyn Connect® or placebo 
for 24 weeks. The network measures in the beta band 
were significantly different between groups. In fact, it 
decreased in the control group, but remained relatively 
unchanged in the supplemented one, suggesting For-
tasyn Connect® role in preventing the progressive net-
work disruption in AD patients. However, these network 
measures were not related to memory performance 
(Tab.  I)  22. Using cumulative data from the Souvenir  I 
(n = 212), Souvenir II (n = 259), S-Connect (n = 527), and 
the OLE of Souvenir II (n = 201), Rijpma et colleagues 
showed that circulating levels of micronutrients and fatty 
acids, including uridine, selenium, folate, vitamin B12, 
vitamin E, vitamin C, DHA and EPA, decreased in the 
AD population and can be increased by 12-48-week 
oral supplementation with Fortasyn Connect® 23. In the 
OLE study, similar levels were reached in former control 
product/initial active product users, whereas 24-week 
continued active product intake showed no sugges-
tion of a further increase in nutrient levels (Tab.  I)  23. 
Furthermore, in another RCT, comparing quantitative 
markers regarding spectral properties, functional con-
nectivity, and graph theoretical aspects of MEG from 
the Souvenir II MEG sub-study in 55 drug-naïve mild AD 
patients, no significant intervention effects were found 
between the Fortasyn Connect® group and the placebo 
one (Tab. I) 24.
Other nutraceutical formulations
Two trials reported significant and promising findings 
on a nutraceutical multinutrient formulation [400 ug folic 
acid, 6 ug B12, 30  I.U. alpha-tocopherol, 400 mg S-
adenosyl methioinine (SAM), 600 mg N-acetyl cysteine, 
and 500 mg acetyl-L-carnitine] in AD and MCI patients 
(Tab I) 25 26. In the first RCT, including 106 AD patients 
randomized to the nutraceutical formulation or placebo 
for 3 or 6 months, followed by an additional nutraceu-
tical formulation supplementation of 6  months, par-
ticipants in the intervention group improved statistically 
versus baseline and placebo in cognitive performance 
evaluated by CLOX-1 (Clock Drawing Test sensitive to 
executive control) and age- and education-adjusted 
Dementia Rating Scale (DRS), and in the memory do-
main of the age-education-adjusted DRS (Tab. I) 25. In 
the second RCT, 34 MCI subjects were randomized for 
6  months to the nutraceutical formulation or placebo 
and then, for another 6-month period, all individuals 
received nutraceutical formulation. Interestingly, the nu-
traceutical formulation cohort improved in the age- and 
education-adjusted DRS and maintained baseline per-
formance in CLOX-1, while the placebo cohort did not 
improve in the age- and education-adjusted DRS and 
declined in CLOX-1, but during the open-label exten-
sion improved in the age- and education-adjusted DRS 
and ceased declining in CLOX-1 (Tab. I) 26.
MultidoMain approach
According to the increasing interest on healthy lifestyle 
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Table I. Randomized clinical trials evaluating the efficacy of nutritional intervention through medical food/nutraceutical supple-
mentation and multidomain approach in the treatment of patients with late-life cognitive disorders aged over 60 years (2014-2016).
Reference Study sample Intervention(s) Duration Cognitive-related 
outcomes and 
nutritional 
assessment
Principal results
Medical food/nutraceutical supplementation
Hartmann et al., 
2014 21
96 drug-naïve mild AD 
patients
Mean age: not reported
Fortasyn Connect®
Placebo
24 weeks Plasma concentration 
of specific PC species
Five of the 7 measured 
PC species were 
significantly increased 
following the
24-week treatment 
with this multinutrient 
combination
de Waal et al., 
2014 22
179 drug-naïve mild AD 
patients
Mean age: 73.3 years
Fortasyn Connect®
Placebo
24 weeks NTB and EEG Significant effects on 
network measures in 
the beta band without 
significant effects on 
cognitive outcomes
Rijpma et al., 
2015 23
1199 drug-naïve mild 
and mild-to moderate 
AD patients
Mean age: 74.5 years
Fortasyn Connect®
Placebo
12-24 weeks Plasma levels of B 
vitamins, choline, 
vitamin E, selenium, 
uridine and 
homocysteine and 
proportions of DHA, 
EPA and total n-3 
PUFAs in plasma and 
erythrocytes
12-24-week active 
product intake 
increased plasma 
and/or erythrocyte 
micronutrients:
uridine, choline, 
selenium, folate, 
vitamins B6, B12 and 
E, and levels of DHA 
and EPA
van Straaten et 
al., 2016 24
55 drug-naïve patients 
with mild AD
Mean age: 69.0 years
Fortasyn Connect®
Placebo
24 weeks EEG and MEG No statistically 
significant intervention 
effects 
Remington et al., 
2015a 25
106 AD patients
Mean age: 77.8 years
Nutraceutical 
formulation (400 ug 
folic acid, 6 ug B12, 30 
I.U. alpha-tocopherol, 
400 mg S-adenosyl 
methioinine (200 mg 
active ion), 600 mg 
N-acetyl cysteine, 
and 500 mg acetyl-L-
carnitine)
Placebo
12 months (3 or 6 
months with a 6-month 
open-label extension 
study)
CLOX-1, DRS, NPI, and 
ADCS-ADL
At 3 months, there was 
cognitive improvement 
for the intervention 
group in CLOX-1 and 
the DRS total score and 
memory domain score
Remington et al., 
2015b 26 
34 MCI patients
Mean age: 62.0 years
Nutraceutical 
formulation (400 ug 
folic acid, 6 ug B12, 30 
I.U. alpha-tocopherol, 
400 mg S-adenosyl 
methioinine (200 mg 
active ion), 600 mg 
N-acetyl cysteine, 
and 500 mg acetyl-L-
carnitine)
Placebo
12 months (6 months 
with a 6-month open-
label extension study)
CLOX-1 and DRS The nutraceutical 
formulation cohort 
improved in the 
DRS and maintained 
baseline performance 
in CLOX-1. The placebo 
cohort did not improve 
in DRS and declined in 
CLOX-1, but during the 
open-label extension 
study improved in DRS 
and ceased declining in 
CLOX-1
Nutritional factors and prevention of late-life cognitive disorders 105
including good dietary habits and physical activity as an 
effective multidomain therapeutic approach for cognitive 
impairment, several studies investigated the efficacy of 
physical exercise programs combined with nutrient sup-
plementations. Epidemiological studies demonstrated 
that links exist between nutrition, physical activity, and 
cognitive and social stimulation that help to improve brain 
health  5. The findings of several RCTs have suggested 
that some single-domain interventions, i.e., antihyper-
tensives, nutritional supplements, cognitive training, and 
physical activity, had protective effects on cognitive de-
cline 39, but these results have seldom been replicated 
in larger samples. As prevention has been advocated as 
an effective way to reduce the burden of AD 40, multid-
omain interventions seem therefore appropriate to target 
the multiple factors involved in cognition and ageing. In 
the last years, some European multidomain intervention 
trials with nutritional guidance, physical exercise, cogni-
tive training and social activities, and management of 
vascular/metabolic risk factors conducted in subjects 
at risk of cognitive decline [Finnish Geriatric Intervention 
Study to Prevent Cognitive Impairment and Disability 
(FINGER)  41 and the Prevention of Dementia by Inten-
sive Vascular care (preDIVA) trial  42] or with subjective 
memory complaints [Multi-domain Alzheimer Preventive 
Trial (MAPT)  43] showed some promising findings with 
beneficial effects on cognition in an at-risk older general 
population 41 and some benefits on dementia incidence 
in at-risk subgroups (i.e., preDIVA participants with un-
treated hypertension at baseline who adhered to the 
intervention)  42. However, we had only limited data on 
patients with established cognitive dysfunction. In a re-
cent RCT, the effect of combined n-3 PUFA supplemen-
tation, aerobic exercise and cognitive stimulation versus 
n-3 PUFA supplementation and non-aerobic exercise 
was evaluated on cognitive function and gray matter 
volume at MRI in patients with MCI (Tab. I) 27. This trial 
demonstrated that n-3 PUFA intake combined with ae-
robic exercise and cognitive stimulation over six months 
led to reduced atrophy in AD-related brain regions of MCI 
patients, compared to n-3 PUFA intake plus the control 
condition of stretching and toning. No significant group 
differences emerged for cognitive parameters over time 
(Tab. I) 27.
Reference Study sample Intervention(s) Duration Cognitive-related 
outcomes and 
nutritional 
assessment
Principal results
Multidomain approach
Köbe et al., 
2016 27
22 MCI patients 
Mean age: 70 years
Multidomain 
intervention with 
n-3 PUFA, aerobic 
exercise and cognitive 
stimulation
Control group
6 months AVLT, TMT-A-B, SCWT, 
forward and backward 
digit spans, verbal 
fluency (semantic and 
phonemic)
Erythrocyte membrane 
fatty acid compositions, 
anthropometric 
measures, serum 
vascular, metabolic 
and inflammatory 
parameters, and 
structural MRI
Gray matter volume 
decreased in the 
frontal, parietal and 
cingulate cortex of 
patients in the control 
group, while 39
gray matter volume 
in these areas was 
preserved or even 
increased after 
the multidomain 
intervention. No 
significant differences 
in cognitive 
performance or other 
vascular, metabolic 
and inflammatory 
parameters were 
observed between 
groups
AD: Alzheimer’s disease; PC: phosphatidylcholine; EEG: electroencephalography; DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; PUFAs: polyunsaturated fatty 
acids; MEG: magnetoencephalography; MRS: magnetic resonance spectroscopy; PME: phosphomonoester; PDE: phosphodiester; tCho: choline-containing compounds; 
MRI: magnetic resonance imaging; CLOX-1: clock drawing task sensitive to executive control; DRS: Dementia Rating Scale; NPI: Neuropsychiatric Inventory; ADCS-ADL: 
Alzheimer’s Disease Cooperative Study – Activities of Daily Living; AVLT: Auditory Verbal Learning Test; TMT-A-B: Trail Making Test part A and B; SCWT: Stroop Color-Word 
Test
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NUTRITIONAL INTERVENTION THROUGH FOOD 
AND MACRONUTRIENT SUPPLEMENTATION
foods
Table II shows selected RCTs published in the last four 
years evaluating the efficacy of nutritional intervention 
using a food or macronutrient approach in the treat-
ment of patients with late-life cognitive disorders aged 
over 60 years 44-52.
Nuts
Considering the known links among late-life cognitive 
decline, AD, and oxidative stress 53 54, Brazil nuts, the 
best food source of an important antioxidant trace ele-
ment, i.e., selenium 55, have been recently investigated 
as a possible source of supplementation for late-life 
cognitive disorders. However, only a few studies have 
investigated whether selenium supplementation can 
benefit cognitive performance, and in most of them, 
selenium was part of a multinutrient supplementa-
tion 33 34 56. Furthermore, none of these RCTs have used 
foods rich in selenium as a source of supplementation. 
Recently, in a small RCT on 31 MCI patients random-
ly assigned to ingestion of Brazil nuts or placebo for 
6  months, verbal fluency, and constructional praxis 
were the cognitive domains significantly improved in the 
supplemented group (Tab. II) 44.
Macronutrients
Lipids
In AD brains, it has been reported a reduction in choline 
acetyltransferase, a biosynthetic enzyme of acetylcho-
line responsible for converting choline into acetylcho-
line  57. Therefore, the first dietary lipids proposed as 
potential therapeutic agents in AD were lecithin, the 
major dietary source of choline, and alpha lipoic acid, 
both able to increase acetylcholine production 58. How-
ever, the first studies documented how use of lecithin, 
after the first exciting results, has not really helped to 
improve the cognitive deficits of treated patients in a 
significant manner 59. Furthermore, a decline of phos-
pholipids in neuronal membranes, particularly phos-
phatidylserine (PS), has been associated with memory 
impairment and deficits in mental cognitive abilities 60 61, 
leading to the proposal that administration of endoge-
nously occurring phospholipids may prevent or reverse 
age-related neurochemical deficits. Recently, early pilot 
studies performed with a brain-health food supplement 
containing a proprietary blend of 100 mg PS and 80 mg 
phosphatidic acid (PA) produced from soy lecithin have 
been proposed  45. Among these studies, a 2-month 
RCT assessed the effect of three PS/PA capsules/day 
(300 mg PS plus 240 mg PA/day) or placebo on daily 
functioning, mental health, emotional state, and self-re-
ported general condition in patients with AD (Tab. II) 45. 
In AD patients, daily functioning (i.e., 7 activities of daily 
living) under PS/PA (n = 53) remained unchanged, but 
declined from 5.62 to 4.90 under placebo (n  =  39), 
with significant group difference. The PS/PA group had 
3.8% deterioration and 90.6% stability in daily function-
ing, compared to 17.9% and 79.5% under placebo. 
The PS/PA patients reported positive trend with a 49% 
improved general condition, compared to 26.3% under 
placebo (Tab. II) 45.
Fatty acids
Many epidemiological studies have demonstrated 
that dietary fatty acids may play a key role in several 
pathological conditions. Long-chain (LC) PUFAs, such 
as DHA, EPA, and arachidonic acid (ARA) are among 
the most studied macronutrients in late-life cognitive 
disorders and neurodegeneration  62. In particular, an 
increasing body of epidemiological evidence suggested 
that elevated saturated fatty acids could have negative 
effects on MCI, while a clear reduction of risk for cogni-
tive decline has been found in population samples with 
elevated fish consumption, high intake of monounsa-
turated fatty acids (MUFAs) and LC PUFAs, particularly 
n-3 PUFAs 63. Despite the strong evidence in cognitive 
decline prevention coming from observational studies, 
findings coming from RCTs in cognitively healthy older 
adults were controversial considering the great hetero-
geneity of samples and outcome measures as well as 
neuropsychological tools or MRI findings 12. In a RCT, 
39 AD patients were randomized for 12 months to pla-
cebo, n-3 PUFA supplementation (fish oil concentrate 
containing a daily dose of 675 mg DHA and 975 mg 
EPA), or the same n-3 PUFA supplementation plus alpha 
lipoic acid (600  mg/day). No difference in ADAS-cog 
between placebo and n-3 PUFA supplementation or 
between placebo and n-3 PUFA supplementation plus 
alpha lipoic acid was reported. For MMSE, there was no 
difference between placebo and n-3 PUFA supplemen-
tation, but a significant difference between placebo and 
n-3 PUFA supplementation plus alpha lipoic acid was 
found (Tab. II).46 In the OmegaAD study, systemic oxi-
dative stress and inflammatory biomarkers were evalu-
ated following oral supplementation of dietary n-3 PUFA 
(1.7 g DHA and 0.6 g EPA) or placebo for 6 months. 
In this RCT, F2-isoprostane in urine increased in the 
placebo group after 6 months, but there was no clear 
difference in treatment effect between supplemented 
and non-supplemented patients on the urinary levels 
of F2-isoprostanes and 15-keto-dihydro-PGF2α. At 
baseline, the levels of 15-keto-dihydro-PGF2α, a major 
metabolite of PGF2α and biomarker of inflammatory re-
sponse, showed negative correlative relationships with 
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Table II. Randomized clinical trials evaluating the efficacy of nutritional intervention using a food/macronutrient approach in the 
treatment of patients with late-life cognitive disorders aged over 60 years (2014-2016).
Reference Study sample Intervention(s) Duration Cognitive-related 
outcomes and 
nutritional 
assessment
Principal results
Food supplementation
Cardoso et al., 
2016 44
31 older subjects with 
MCI 
Mean age: 77.7 years
Daily Brazil nut intake 
(estimated 288.75 µg 
of selenium)
Placebo 
6 months CERAD 
neuropsychological 
test battery total 
score, CERAD subtests 
(verbal fluency, BNT, 
constructional praxis, 
word list learning test, 
and word list recall)
Blood selenium 
concentrations, 
erythrocyte glutathione 
peroxidase activity, 
oxygen radical 
absorbance capacity, 
and malondialdehyde
In the supplemented 
group there 
were significant 
improvement of some 
cognitive domains, 
i.e., verbal fluency and 
constructional praxis
Macronutrient approach
Lipids
Moré et al., 
2014 45
96 patients with AD
Aged 50-90 years
100 mg 
phosphatidylserine plus 
80 mg phosphatidic 
acid in lecithin three 
times daily
Placebo (starch)
2 months 7-ADL, MMSE, and
RDT
Significant positive 
effect of this 
supplementation on 
daily functioning,
positive trends on 
emotional state and on 
self-reported general 
condition. No adverse 
effects were reported
Fatty acids
Shinto et al., 
2014 46
39 AD patients
Mean age: 75.9 years
n-3 PUFAs 
n-3 PUFAs + alpha-
lipoic acid 
Placebo
12 months ADAS-cog, MMSE, ADL, 
and IADL
No difference in 
ADAS-cog between 
placebo and n-3 PUFA 
supplementation or 
between placebo 
and n-3 PUFA 
supplementation 
plus alpha lipoic acid 
was reported. For 
MMSE, there was no 
difference between 
placebo and n-3 PUFA 
supplementation, 
but a significant 
difference between 
placebo and n-3 PUFA 
supplementation plus 
alpha lipoic acid was 
found
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Reference Study sample Intervention(s) Duration Cognitive-related 
outcomes and 
nutritional 
assessment
Principal results
Fatty acids
Freund-Levi et 
al., 2014a 47
40 moderate AD 
patients 
Mean age: 70.5 years
n-3 PUFA (1.7 g DHA 
and 0.6 g EPA) 
Placebo
6 months Urinary levels of F2-
isoprostane, 8-iso-
PGF2α, and 15-keto-
dihydro-PGF2α
F2-isoprostane in 
urine increased in the 
placebo group after 6 
months, but there was 
no clear difference 
in treatment effect 
between supplemented 
and non-supplemented 
patients on the 
urinary levels of F2-
isoprostanes and 
15-keto-dihydro-PGF2α
Freund-Levi et 
al., 2014b 48
33 mild-to-moderate 
AD patients 
Age: over 65 years
n-3 PUFA (1.7 g DHA 
and 0.6 g EPA) 
Placebo
6 months CSF PUFA levels, 
plasma PUFA levels, 
and CSF biomarkers of 
AD and inflammation
The n-3 PUFA 
supplemented group 
displayed significant 
increases in CSF and 
plasma EPA, DHA 
and total n-3 PUFA 
levels, whereas no 
changes were found 
in the placebo group. 
Changes in DHA 
levels in CSF were 
inversely correlated 
with CSF levels of total 
and phosphorylated 
tau, and directly 
correlated with soluble 
interleukin-1 receptor 
type II
O’Callaghan et 
al., 2014 49
33 MCI patients 
Age: over 65 years
EPA-rich fish oil (1.67 g 
EPA plus 0.16 g DHA/
day), 
DHA-rich fish oil 
(1.55 g DHA plus 
0.40 cg EPA/day)
 LA (safflower oil, LA 
2.2 g/day)
6 months Telomere length Telomere shortening 
was greatest in the 
LA group than in 
the DHA and EPA 
groups. Increased 
erythrocyte DHA levels 
were associated with 
reduced telomere 
shortening in the DHA 
group
Eriksdotter et al., 
2015 50
165 AD patients 
Mean age: 72.5 years 
n-3 PUFA (1.7 g DHA 
and 0.6 g EPA) 
Placebo
Subsequently, all 
patients received the 
n-3 PUFA formulation 
for the next 6 months
12 months ADAS-cog, MMSE, and 
plasma PUFA levels
A signiﬁcant positive 
association between 
the changes of 
plasma DHA levels 
and changes of total 
scores of ADAS-cog. No 
significant correlation 
between changes of 
n-3 PUFA levels and 
changes of MMSE 
scores nor any of its 
sub-items
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n-3 PUFAs, and a positive correlation to the n-6 PUFA 
linoleic acid (LA), while 8-iso-PGF2α, a consistent in vivo 
biomarker of oxidative stress, correlated negatively to 
the n-6 PUFA ARA (Tab. II) 47. Findings from the same 
RCT, the OmegaAD study, on 33 moderate AD patients 
suggested that at 6 months the n-3 PUFA supplement-
ed group (1.7 g DHA and 0.6 g EPA) showed significant 
increases in cerebrospinal fluid (CSF) and plasma EPA, 
DHA and total n-3 PUFA levels, whereas no changes 
were observed in the placebo group. Changes in CSF 
and plasma levels of EPA and n-3 PUFA docosapentae-
noic acid were strongly correlated, in contrast to those 
of DHA. Changes in DHA levels in CSF were inversely 
correlated with CSF levels of total and phosphorylated 
tau, and directly correlated with soluble interleukin-1 
receptor type II (Tab. II) 48. In 33 MCI patients aged over 
65 years, randomized to receive a supplement rich in 
the long-chain n-3 PUFAs EPA (1.67 g EPA plus 0.16 g 
DHA/day) or DHA (1.55 g DHA plus 0.40 g EPA/day) 
versus n-6 PUFA LA (2.2 g/day) for 6 months, telomere 
shortening, a marker of accelerated aging also linked 
to cognitive ability and MCI  64, was greater in the LA 
group than in the DHA and EPA groups. Increased 
erythrocyte DHA levels were associated with reduced 
telomere shortening in the DHA group. These findings 
suggested that telomeric shortening may be attenuated 
by n-3 PUFA supplementation (Tab. II) 49. Other findings 
from the OmegaAD study on 165 AD patients showed 
a signiﬁcant positive association between the changes 
of plasma DHA levels and changes of total ADAS-cog 
scores suggesting a potential protective role of increas-
ing plasma n-3 PUFA levels in preservation of cognitive 
functioning. However, changes of plasma n-3 PUFA 
levels and changes MMSE scores and its sub-items 
were not significantly related (Tab.  II)  50. On the other 
hand, no significant findings on cognitive, depressive, 
and functional domains have been reported in another 
RCT including 76 participants [57 with cognitive impair-
ment no dementia (CIND) and 19 with AD] randomized 
to receive either n-3 PUFAs (600 mg EPA and 625 mg 
DHA per day) or placebo for 4 months (Tab.  II)  51. Fi-
nally, in the Alzheimer’s Disease Cooperative Study 
(ADCS)-sponsored DHA clinical trial, at baseline, there 
were no significant differences between CSF or plasma 
DHA levels by CSF Aβ1-42 tertiles or apolipoprotein E 
(APOE) ε4 status in AD patients supplemented with 2 g/
day of DHA or AD patients assuming placebo (Tab. II) 52. 
After 18 months of DHA supplementation, participants 
Reference Study sample Intervention(s) Duration Cognitive-related 
outcomes and 
nutritional 
assessment
Principal results
Fatty acids
Phillips et al., 
2015 51
76 participants with 
CIND or AD 
Mean age: 71.1 years
n-3 PUFAs (600 mg 
EPA and 625 mg DHA 
per day)
Placebo (olive oil)
4 months MMSE, HVLTR, 
MMSES7, MMSEWB, 
BASDEC, other 
neuropsychological 
mesures of executive 
functioning, language, 
verbal reasoning, visual 
memory, and BADLS
No significant 
effects on cognitive, 
depressive, and 
functional outcomes
Yassine et al., 
2016 52
70 AD patients 
Mean age: not reported
Algae-derived DHA oil 
(2 g/day of DHA)
Placebo (corn/soy oil)
18 months Plasma and CSF DHA 
levels, CSF Aß1-42, tau, 
and phosphorylated 
tau.
APOE genotype
After 18 months of 
DHA supplementation, 
APOE ε4 allele and 
lower CSF Aß1-42 levels 
were associated with 
less transport of DHA 
to CSF. These findings 
may suggest that brain 
amyloid pathology may 
limit the delivery of 
DHA to the brain in AD
MCI: mild cognitive impairment; CERAD: Consortium to Establish a Registry for Alzheimer’s Disease; ADAS-Cog: Alzheimer’s disease Assessment scale, Cognitive sub-
scale; VLT: Verbal Learning Test-Revised; MMSE: Mini Mental State Examination; FCSRT: Free and Cued Selective Reminding Test; PS: phosphatidylserine; PA: phosphatid-
ic acid; AD: Alzheimer’s disease; ADL: activities of daily living; RDT: Tel-Aviv University Rosen Target Detection test; PUFAs: polyunsaturated fatty acids; IADL: instrumental 
activities of daily living; DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; CSF: cerebrospinal fluid; LA: linoleic acid; CIND: cognitive impairment no dementia; 
HVLTR: Hopkins Verbal Learning Test-Revised; MMSES7: mini mental state examination Serial Sevens; MMSEWB: mini-mental state examination World Backwards; 
BASDEC: Brief Assessment Schedule Depression Cards; BADLS: Bristol’s Activities of Daily Living Scale; Aß: amyloid ß; APOE: apolipoprotein E
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at the lowest Aβ1-42 tertile had significantly lower CSF 
DHA levels and lower CSF-to-plasma DHA ratios com-
pared to the other tertiles. Baseline CSF Aβ1-42 levels 
were significantly lower in APOE ε4 carriers than in 
APOE ε4 noncarriers. Participants carrying the ε4 allele 
demonstrated a less pronounced increase in CSF DHA 
level compared with noncarriers, with a possible inter-
action effect between treatment and APOE genotype. 
These findings suggested that APOE ε4 allele and lower 
CSF Aβ1-42 levels were associated with less transport of 
DHA to CSF (Tab. II) 52.
NUTRITIONAL INTERVENTION THROUGH 
MICRONUTRIENT CHANGES
antioxidants vitaMins and trace eleMents
Table III shows selected RCTs published in the last four 
years evaluating the efficacy of nutritional intervention 
through supplementation of dietary micronutrients in 
the treatment of patients with late-life cognitive disor-
ders aged over 60 years 65-73. Given the suggested re-
lationship between cognitive impairment and oxidative 
stress  53 54, and consequently cell death, membranes 
peroxidation, and Aβ deposition, several antioxidant vi-
tamins or minerals and trace elements with antioxidant 
properties have been proposed for the treatment of AD, 
MCI, and other late-life cognitive disorders 56. Howev-
er, findings coming from RCTs were contrasting  16. In 
a RCT including 561 AD patients assigned to receive 
2000 IU/day of vitamin E (alpha tocopherol), 20 mg/d of 
memantine, the combination, or placebo, no significant 
findings have been reported on cognitive outcomes 
(MMSE, ADAS-cog). However, ADCS-Activities of Dai-
ly Living Inventory scores declined significantly less in 
the vitamin E group compared with the placebo one, 
suggesting a beneficial effect in slowing functional de-
cline in AD patients (Tab. III) 65. Furthermore, in another 
trial including 256  MCI subjects assigned to receive 
either 300 mg of vitamin E plus 400 mg vitamin C per 
day or placebo for one year, no significant differences 
in MMSE score were reported, despite significant im-
provement in most of the oxidative stress biomarkers 
measured (Tab.  III)  66. Among trace elements with an-
tioxidant properties, selenium was part of multinutrient 
supplementations in AD 33 34 56. In a 24-week Phase IIa 
RCT, 40 mild-to-moderate AD patients (MMSE 14-26) 
with a mean age of 70.5 years were randomized to a 
supranutritional sodium selenate group (VEL015 10 mg 
three times per day), chosen for its selenium content 
and high solubility, or control (VEL015 320  μg three 
times per day) or placebo groups. Exploratory biomark-
ers included cognitive tests, neuroimaging (diffusion 
MRI and FDG-PET), and CSF (p-tau, t-tau, and Aß1-42). 
No significant differences between the supranutritional 
and control groups were observed for cognition, CSF, 
and FDG-PET biomarkers. Only one secondary biomar-
ker, diffusion MRI measures, showed group differences, 
with less deterioration in the supranutritional group 
(Tab. III) 67.
hoMocysteine-related vitaMins
A possible modifiable risk factor of dementia is an el-
evated plasma homocysteine (Hcy) level. In fact, Hcy 
may be toxic for neurons and vascular endothelial 
cells  74, and cross-sectional and prospective studies 
have shown associations between elevated Hcy lev-
els and cognitive decline and dementia  75. Hcy levels 
can be lowered by supplementation with folic acid (vi-
tamin B9) and vitamin B12  76. Although observational 
studies have shown a strong association between poor 
vitamin B6, B12, and folate levels and increased risk of 
dementia, suggesting a preventive and protective role 
of these micronutrients, evidence from RCTs appeared 
to be unclear 12. Findings from the Homocysteine and 
B Vitamins in Cognitive Impairment (VITACOG) trial on 
168 MCI patients, randomly assigned either to placebo 
(n = 83) or to daily high-dose B vitamin supplementa-
tion (folic acid, 0.8 mg; vitamin B6, 20 mg; vitamin B12, 
0.5 mg) (n = 85) suggested that after 2 years of supple-
mentation there was a significant interaction between 
B vitamin treatment and plasma combined n-3 PUFA 
(EPA and DHA) on brain atrophy rates at MRI (Tab. III) 68. 
In MCI subjects with high plasma concentrations of 
n-3 PUFA (EPA+DHA 0.590  mmol/L), B  vitamin sup-
plementation slowed the mean brain atrophy rate by 
40% compared with subjects in the placebo group. 
In contrast, in MCI subjects with low n-3 PUFA con-
centrations (0,390  mmol/L), there was no beneficial 
effect of B vitamins on brain atrophy (Tab. III) 68. Other 
findings from the VITACOG trial including 266 MCI sub-
jects randomized to B vitamins (folic acid, vitamins B6 
and B12) or placebo for 2 years, final scores for verbal 
delayed recall (episodic memory), global cognition, and 
CDR-SB scores were better in the B  vitamin-treated 
group according to increasing baseline plasma con-
centrations of n-3 PUFAs, whereas in the placebo 
group scores were similar across these concentra-
tions. These findings suggested that at low n-3 PUFA 
concentrations, B  vitamin treatment had no effect on 
cognitive decline in MCI. However, at n-3 PUFA plasma 
levels in the upper normal range, B vitamins might slow 
cognitive decline.  In particular, DHA in this study was 
more effective than EPA in enhancing the cognitive ef-
fects of B vitamins (Tab. III) 69. In another RCT including 
159  MCI subjects randomized to a daily intervention 
of 400 μg folic acid versus placebo for 6 months, folic 
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Table III. Randomized clinical trials evaluating the efficacy of nutritional intervention using a micronutrient approach in the treat-
ment of patients with late-life cognitive disorders aged over 60 years (2014-2016).
Reference Study sample Intervention(s) Duration Cognitive-related 
outcomes and 
nutritional 
assessment
Principal results
Antioxidant vitamins and trace elements
Dysken et al., 
2014 65
561 AD patients 
Mean age: 78.8 years
2000 IU/d of vitamin E 
(alpha tocopherol)
20 mg/d of memantine
2000 IU of vitamin E 
(alpha tocopherol) + 
20 mg/d of memantine
Placebo
5 years 
(mean follow up: 
2.3 years)
ADCS-ADL Inventory, 
ADAS-cog, MMSE, NPI, 
CAS, and Dependence 
Scale
No significant effects 
on cognitive outcomes
Naeini et al., 
2014 66
256 subjects with MCI 
Mean age: 66.4 years
300 mg of vitamin E 
plus 400 mg of 
vitamin C/day
Placebo
1 year MMSE
Serum oxidative stress 
markers
 
Three-day dietary 
record forms
Despite significant 
improvement in most of
the oxidative stress 
biomarkers, no 
significant effects on 
cognitive outcomes
Malpas et 
al., 2015 67
40 mild-to-moderate 
AD patients
Mean age: 70.5 years
Supranutritional sodium 
selenate group (VEL015 
10 mg three times per 
day)
Control group (VEL015 
320 μg three times 
per day)
Placebo
24 weeks MMSE, ADAS-Cog, 
COWAT, CFT, and 3 
tests from the CogState 
computerized battery: 
OCL, IDN, and DET
Diffusion MRI and FDG-
PET
CSF biomarkers
Only one secondary 
biomarker, diffusion
MRI measures, showed 
group differences, with 
less deterioration in the 
supranutritional group
Homocysteine-related vitamins
Jernerén et al., 
2015 68
168 subjects with MCI
Mean age: 76.6 years
Daily high-
dose B vitamin 
supplementation (folic 
acid, 0.8 mg; vitamin 
B6, 20 mg; vitamin 
B12, 0.5 mg)
Placebo
2 years Structural MRI
Plasma n-3 PUFA
A significant interaction 
effect between 
high-dose B vitamin 
treatment and n-3 
PUFA concentrations on 
rate of atrophy of the 
whole brain was found.
The beneficial effect 
of high-dose B vitamin 
supplementation
was augmented by a 
high baseline status of 
plasma n-3 PUFA
Oulhaj et al., 
2016 69
266 subjects with MCI
Mean age: 76.8 years
Daily high-
dose B vitamin 
supplementation (folic 
acid, 0.8 mg; vitamin 
B6, 20 mg; vitamin 
B12, 0.5 mg)
Placebo
2 years HVLT-DR, TICS-M, and 
CDR
Plasma n-3 PUFA 
APOE genotype
When n-3 PUFA 
concentrations 
were low, B vitamin 
treatment had no effect 
on cognitive decline 
in MCI, but when n-3 
PUFA levels were in the 
upper normal range, 
B vitamins interacted to 
slow cognitive decline
u
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Reference Study sample Intervention(s) Duration Cognitive-related 
outcomes and 
nutritional 
assessment
Principal results
Homocysteine-related vitamins
Ma et al., 
2016 70
159 subjects with MCI
Mean age: 74.7 years
Folic acid (400 µg/day)
Placebo
6 months WAIS-RC and MMSE 
Serum Hcy, SAM, 
SAH, folic acid, and 
vitamin B12 
Folic acid group had 
statistically significant 
increase in global 
cognitive function 
(WAIS-RC) and some 
WAIS-RC sub-tests 
investigating short-
term verbal memory 
and visuoconstructional 
ability
Chen et 
al., 2016 71
121 patients with AD
Mean age: 67.9 years
Donepezil /10 mg /
day) plus folic acid 
(1.25 mg/day)
Donepezil /10 mg /day)
6 months MMSE
Serum folate, Aß, IL-6, 
TNFα, plasma Hcy, 
SAM, SAH, and the 
mRNA levels of PS, 
IL-6, and TNF-α in 
leukocytes
The mean MMSE was 
slightly increased in 
the intervention group 
compared to that in the 
control group. Post-
treatment plasma SAM 
and SAM/SAH levels 
were significantly 
higher, while Aß1-
40, PS1-mRNA, and 
TNFα-mRNA levels 
were lower in the 
intervention group than 
in the control group. 
The Aß1-42/Aß1-40 ratio 
was also higher in the 
intervention group
Flavonoids and carotenoids
Gleason et al., 
2015 72
65 AD patients 
Mean age: 79 years
Soy isoflavones 
(100 mg/day) 
Placebo
6 months List Learning, 
Paragraph Recall, BVRT, 
CFR, phonemic fluency, 
animal fluency, Digit 
Symbol, Digit Span, 
SCWT, Mazes, TMT-
A-B, CFC, and GPB 
APOE genotype and 
plasma isoflavone 
levels
No cognitive benefits 
over placebo 
after 6 months of 
supplementation, 
and global cognition 
declined at similar 
rates in both treatment 
and control groups 
Nolan et al., 
2016 73
31 AD patients and 
31 age-similar control 
subjects
Mean age: 78 years
Carotenoids (10 mg 
meso-zeaxanthin, 
10 mg lutein, 
2 mg zeaxanthin)
Placebo (sunflower oil)
6 months MMSE, phonemic 
fluency, animal fluency, 
and three tasks from 
the CANTAB
No significant effects 
on all cognitive 
outcomes
AD: Alzheimer’s disease; ADCS-ADL: Alzheimer’s Disease Cooperative Study-Activities of Daily Living; ADAS: Alzheimer’s Disease Assessment Scale; MMSE: Mini Mental 
State Examination; NPI: Neuropsychiatric Inventory; CAS: Caregiver Activity Survey; MCI: mild cognitive impairment; COWAT: Controlled Oral Word Association Test; CFT: 
Category Fluency Test; OCL: one-card learning memory task; IDN: identification reaction time task; DET: detection reaction time task; MRI: magnetic resonance imaging; 
FDG-PET: fluorodeoxyglucose positron emission tomography; CSF: cerebrospinal fluid; PUFA: polyunsaturated fatty acids; HVLT-DR: Hopkins verbal learning test with de-
layed recall; TICS-M: telephone inventory for cognitive status-modified; CDR: Clinical Dementia Rating; APOE: apolipoprotein E; WAIS-RC: Chinese version of the Wechsler 
Adult Intelligence Scale-Revised; Hcy: homocysteine; SAM: S-adenosylmethionine; SAH: S-adenosyl homocysteine; Aß: amyloid ß; PS: presenilin; IL-6: interleukin-6; 
TNF-α: tumor necrosis factor α; BVRT: Benton Visual Retention test; CFR: Complex Figure Recall; SCWT: Stroop Color Word test; TMT-A-B: trail making test part A and B; 
CFC: Complex Figure Copy; GPB: Grooved Peg Board; CANTAB: Cambridge Neuropsychological Test Automated Battery
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acid supplementation was associated with a significant 
increase in global cognitive function (Chinese version of 
the Wechsler Adult Intelligence Scale-Revised, WAIS-R) 
and some WAIS-RC sub-tests investigating short-term 
verbal memory and visuoconstructional ability, probably 
related to reduced Hcy levels also observed in this trial 
after six months, and even after 3 months of supple-
mentation (Tab.  III)  70. Finally, in another RCT, 121 AD 
being treated with donepezil were randomly assigned 
into two groups with (intervention group) or without 
(control group) supplemental treatment with folic acid 
(1.25 mg/d) for 6 months. The mean MMSE was slightly 
increased in the intervention group compared to that in 
the control group. Folic acid supplementation improved 
also markers of inflammation suggesting that folic acid 
may be beneficial in patients with AD in concert with 
donepezil and that inflammation may play an import-
ant role in the interaction between folic acid and AD 
(Tab. III) 71.
flavonoids
Flavonoids [flavanols (catechin, epicatechin, epigallo-
cathechin, and epigallocatechingallate-EGCG), flavo-
nols (quercetin and kaempferol), flavones (luteolin and 
apigenin), isoflavones (daidzein and genistein), flava-
nones (esperetin and naringenin), and anthocyanidins 
(pelargonidin, cyanidine, and malvidin) have also been 
proposed to prevent or treat cognitive impairment or 
dementia 77 78. The polyphenol subgroups of flavanols, 
anthocyanins and flavanones have been shown to be 
the most beneficial in terms of neuroprotection 79. Re-
cent RCTs showed significant improvements in some 
cognitive domains after flavonoid interventions 80. How-
ever, the great heterogeneity in sample, flavonoid dose, 
follow-up and cognitive tests used led to inconsistent 
findings  80. In a RCT, 65 AD patients over the age of 
60 were treated with 100  mg/day soy isoflavone, or 
matching placebo capsules for six months. Although 
no significant differences in treatment effects emerged 
on cognitive outcomes between treatment groups or 
genders, among individuals who were effectively able 
to metabolize the soy isoflavone daidzein to equol, data 
suggested an association between plasma levels of 
equol and performance on verbal fluency and speeded 
manual dexterity (Tab. III) 72.
carotenoids
Carotenoids lutein and zeaxanthin are found in certain 
fruits and vegetables (i.e., spinach, broccoli, peppers, 
melon) 81, while meso-zeaxanthin has been identified in 
fish 82 and is also believed to be generated from lutein at 
the retina 83. High carotenoid intake has been found to 
result in a reduced risk of AD 84. Nonetheless, recent in-
terventional studies administering lutein and zeaxanthin 
have shown improvement in different domains of cog-
nition in patients free of AD 85 86. Indeed, a RCT in 31 
patients with AD and 31  age-similar control subjects 
who were supplemented with carotenoids (10  mg 
meso-zeaxanthin, 10  mg lutein, 2  mg zeaxanthin) or 
placebo (sunflower oil) found no benefit in measures of 
cognitive function performed in the trial. However, the 
active supplement improved visual function (contrast 
sensitivity) in AD and control groups (Tab. III) 73.
DISCUSSION
The association between diet and cognitive function or 
dementia has been largely investigated in observational 
studies 4, while there was a lack of evidence from RCTs 
dealing with the treatment of AD and other late-life 
cognitive disorders though dietary interventions. In-
deed, in the last four years, several meta-analyses and 
systematic/scoping reviews investigated the efficacy 
of different nutritional supplementations in preventing 
late-life cognitive disorders in cognitively healthy older 
adults  8-12. However, there were fewer similar studies 
on patients with dementia, AD, or MCI 13-16. In the pres-
ent article, we systematically reviewed RCTs published 
in the last four years exploring nutritional intervention 
efficacy in slowing cognitive impairment progression 
and achieving cognitive-related outcomes in patients 
aged 60 years and older with late-life cognitive disor-
ders, using different levels of investigation (i.e., med-
ical food/nutraceutical supplementation/multidomain 
approach and dietary food/macro- and micronutrient 
approaches). In the present systematic review, we in-
cluded studies focusing on dementia, AD, prodromal 
AD, MCI, and different models of late-life cognitive im-
pairment/decline, but we did not find studies focusing 
in particular on nutritional intervention for VaD. From 
the reviewed RCTs, there was emerging evidence 
that nutritional intervention through medical food/nu-
traceutical supplementation (Fortasyn Connect®) and 
multidomain approach improved MRI findings and 
cognitive-related biomarkers (plasma lipid biomarker 
profile prognostic of AD, EEG findings, and circulating 
levels of supplemented micro- and macronutrients), but 
without clear effect on cognition in mild AD and MCI 
and with one substantially negative MEG study. How-
ever, another nutraceutical formulation showed positive 
effects on specific cognitive domains in AD and MCI 
patients (Tab.  I). Moreover, for food supplementation, 
there was some evidence of a positive effect of anti-
oxidant-rich foods (nuts) in improving specific cognitive 
domains and cognitive-related outcomes in MCI and 
mild-to-moderate dementia, but only in small samples 
(Tab.  II). For lipid supplementation, there were only 
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limited effects of phospholipids in MCI and mild AD, 
while there was convincing evidence for fatty acid sup-
plementation, mainly n-3 PUFAs, in improving specific 
cognitive domains and/or cognitive-related biomarkers 
in MCI and AD (Tab.  II). Furthermore, among selected 
RCTs that evaluated the efficacy of nutritional interven-
tion through supplementation of dietary micronutrients, 
there was evidence for antioxidant vitamin and trace 
element supplementations of an impact in improving 
only cognitive-related outcomes and biomarkers, with-
out effect on cognitive function in AD and MCI patients 
(Tab.  III). For Hcy-related vitamin supplementation, 
there was evidence of an impact of high-dose B vitamin 
supplementation in AD and MCI patients in improving 
cognitive outcomes but only in the subjects with a 
high baseline status of plasma n-3 PUFA, and of folic 
acid supplementation in improving specific cognitive 
domains. Finally, there was no evidence of significant 
improvement in cognitive outcomes after flavonoid and 
carotenoid supplementations (Tab. III).
In the last four years, some meta-analyses and sys-
tematic reviews investigated the efficacy of different 
nutritional supplementations for the treatment of AD 
and other late-life cognitive disorders  13-16 78. For pa-
tients with MCI, AD, or dementia, other recent system-
atic reviews and meta-analyses investigating less re-
cent RCTs suggested some efficacy of medical foods/
nutraceuticals in specific cognitive domains at early 
stage of AD 15 or in patients with dementia, AD, and 
MCI with also neuropsychological symptoms  78. An 
increasing body of evidence suggested that Fortasyn 
Connect® could have clinically detectable effects in 
early AD patients 37. In fact, considering that synapses 
formation is compromised by the neurodegeneration 
characterizing the later stages of AD, the potential 
beneficial effect on neuroprotection and synaptogen-
esis of Fortasyn Connect® may be limited in later AD 
stages compared with earlier ones  37. Furthermore, 
other systematic reviews found no convincing evi-
dence for the efficacy of n-3 PUFA supplements in the 
treatment of mild to moderate AD, at least on cog-
nitive outcomes  14, or vitamin E supplementations in 
people with MCI to prevent progression to dementia, 
or improve cognitive function in people with MCI or 
dementia due to AD 16. Finally, another systematic re-
view and meta-analysis found weak evidence of ben-
efits with vitamins B supplementation for the domain 
of memory in patients with MCI, with no significant 
cognitive benefits in AD patients  13. Therefore, while 
there were encouraging findings with specific dietary 
supplementations in the earlier phases of AD or MCI, 
results from RCTs were contrasting for moderate AD 
patients probably based also on a great heterogeneity 
in sample size.
In the last years, considering the known less efficacy 
of single nutrients versus combined ones in improv-
ing cognitive function and the bidirectional interaction 
between cognitive and physical dimensions in older 
age  87, several studies proposed medical foods or a 
multidimensional approaches, including supplements 
and physical activity, with some promising results in 
subjects with and without cognitive impairment 27 41-43, 
particularly in at-risk subgroups. Considering evidence 
showing a greater efficacy of nutritional intervention in 
earlier stage of AD, it is necessary to increase disease 
biomarkers use in order to allow diagnosis in the earlier 
phase of cognitive dysfunction, i.e., subjective memory 
decline 88, so identifying subjects at risk of developing 
AD and dementia. 
However, some limitations should be reported for the 
present systematic review article. An important limitation 
was linked to the great heterogeneity of included RCTs 
not only in terms of study samples and trial durations, 
but also in relation to the outcome measures and nu-
trients intake quantification. This heterogeneity made 
really difficult to give clear answers about the efficacy 
of dietary intervention in older adults without cognitive 
dysfunction. However, there are several interesting con-
cepts coming from the reviewed RCTs to underline. The 
first one was the emerging use of innovative measures 
of dietary habits, not only daily semi-quantitative food 
frequency questionnaires but also biomarker dosages 
such as blood exams or urinary excretion. This resulted 
into an objective quantification of nutrient supplementa-
tion but also of nutritional status of patients at baseline. 
Furthermore, as shown in the present systematic review, 
recent RCTs underlined the importance to consider 
emerging cognitive-related outcomes in order to achieve 
more clinically focused and reliable findings. Therefore, in 
addition to clinical scales and neuropsychological tests, 
serum, CSF, neuroimaging, and other cognitive-related 
biomarkers have been proposed. The result was an 
objective quantification of dietary habits and nutritional 
state of patients at baseline and of the nutrition-related 
impact on cognitive impairment and AD pathobiology to 
achieve more clinically focused and reliable findings. In 
conclusion, medical food/nutraceutical supplementation 
(Fortasyn Connect® and another similar combinatorial 
formulation), nutritional interventions with antioxidant-rich 
foods (nuts), and macronutrient (n-3 PUFAs) and micro-
nutrient (antioxidant and Hcy-related vitamins) supple-
mentations could be really effective in achieving cogni-
tive-related outcomes in MCI and AD patients. However, 
to obtain more statistically significant and reliable results, 
RCTs would be conducted in larger selected samples 
characterized by well defined cognitive function status, 
nutritional and dietary habits at baseline, with longer fol-
low-up, and would include further objective measures of 
Nutritional factors and prevention of late-life cognitive disorders 115
cognitive-related outcomes as blood or CSF biomarkers 
and neuroimaging findings.
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